Seaport Therapeutics, Inc. Common Stock (SPTX)

Seaport Therapeutics, Inc. Common Stock (SPTX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $986M; returns 1 day -0.7%, 1 week +15.6%.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oral neuropsychiatric medicines for depression, anxiety, and other central nervous system (CNS) disorders. The company's core economic engine is its proprietary Glyph technology platform, a lymphatic-targeting prodrug system designed to bypass first-pass liver metabolism.

Groups SPTX belongs to

• Recent IPOs
• Clinical Stage Biopharma
• Biotechnology
• CNS Disorders
• Neuroscience
• Neurological Disorders
• Biopharmaceutical
• Clinical Stage
• Drug Discovery
• Healthcare Innovation
• Life Sciences

SPTX financial model: income statement, cash flow and balance sheet